PE20241994A1 - Proteina mutante de interleucina-2 y fusion de la misma - Google Patents

Proteina mutante de interleucina-2 y fusion de la misma

Info

Publication number
PE20241994A1
PE20241994A1 PE2024000528A PE2024000528A PE20241994A1 PE 20241994 A1 PE20241994 A1 PE 20241994A1 PE 2024000528 A PE2024000528 A PE 2024000528A PE 2024000528 A PE2024000528 A PE 2024000528A PE 20241994 A1 PE20241994 A1 PE 20241994A1
Authority
PE
Peru
Prior art keywords
mutant protein
fusion
immunoconjugate
dimer
interleukin
Prior art date
Application number
PE2024000528A
Other languages
English (en)
Spanish (es)
Inventor
Kaijie He
Fenggen Fu
Weiwei Wu
Shuaixiang Zhou
Jian Guan
Original Assignee
Fortvita Biologics Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fortvita Biologics Singapore Pte Ltd filed Critical Fortvita Biologics Singapore Pte Ltd
Publication of PE20241994A1 publication Critical patent/PE20241994A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PE2024000528A 2021-09-22 2022-09-21 Proteina mutante de interleucina-2 y fusion de la misma PE20241994A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111110032 2021-09-22
PCT/CN2022/120265 WO2023045977A1 (zh) 2021-09-22 2022-09-21 白介素2突变体以及其融合蛋白

Publications (1)

Publication Number Publication Date
PE20241994A1 true PE20241994A1 (es) 2024-09-27

Family

ID=85720093

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000528A PE20241994A1 (es) 2021-09-22 2022-09-21 Proteina mutante de interleucina-2 y fusion de la misma

Country Status (14)

Country Link
US (2) US20240391973A1 (enExample)
EP (1) EP4406965A4 (enExample)
JP (2) JP7864826B2 (enExample)
KR (1) KR20240082364A (enExample)
CN (1) CN118119635A (enExample)
AU (2) AU2022350407B2 (enExample)
CA (1) CA3233075A1 (enExample)
CL (1) CL2024000834A1 (enExample)
CO (1) CO2024004910A2 (enExample)
IL (1) IL311643A (enExample)
MX (1) MX2024003535A (enExample)
PE (1) PE20241994A1 (enExample)
TW (1) TWI858393B (enExample)
WO (1) WO2023045977A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112105634B (zh) 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
KR20220155316A (ko) * 2020-03-19 2022-11-22 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 인터루킨-2 돌연변이 및 이의 용도
WO2025007037A1 (en) * 2023-06-28 2025-01-02 Dragonfly Therapeutics, Inc. Variant il-2 proteins
WO2025031434A1 (zh) * 2023-08-08 2025-02-13 北京志道生物科技有限公司 经修饰的细胞因子与cd40激动剂的联用组合物及其抗肿瘤用途
AU2024411090A1 (en) 2023-12-28 2026-07-16 Fortvita Biologics (Singapore) Pte. Ltd. Pd-1/il-2r bispecific antibody fusion protein, and use and usage method thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
CN118373896B (zh) * 2024-04-19 2025-07-29 上海科棋药业科技有限公司 抗pd-1抗体与il-2突变体的双功能融合蛋白
WO2025252212A1 (zh) * 2024-06-07 2025-12-11 福佑泰生物制药公司 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用
WO2026012466A1 (en) * 2024-07-12 2026-01-15 Vibrant Pharma Limited Interleukin-2 muteins and uses thereof
CN118546233B (zh) * 2024-07-30 2024-10-18 成都微芯新域生物技术有限公司 白介素-21突变体及其应用
WO2026083295A1 (en) * 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
CN121293311B (zh) * 2025-08-01 2026-07-24 合肥天港免疫药物有限公司 Il-2变体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
JP7765181B2 (ja) * 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
CN111868079B (zh) * 2017-12-27 2025-06-17 协和麒麟株式会社 Il-2变体
CN112105634B (zh) * 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
CA3143034A1 (en) * 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
KR20220155316A (ko) * 2020-03-19 2022-11-22 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 인터루킨-2 돌연변이 및 이의 용도
WO2021185362A1 (zh) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 白介素2突变体及其用途

Also Published As

Publication number Publication date
TW202320862A (zh) 2023-06-01
US20260053898A1 (en) 2026-02-26
EP4406965A1 (en) 2024-07-31
AU2025275202A1 (en) 2026-02-19
CO2024004910A2 (es) 2024-07-08
CA3233075A1 (en) 2023-03-30
WO2023045977A1 (zh) 2023-03-30
US20240391973A1 (en) 2024-11-28
CL2024000834A1 (es) 2024-09-06
EP4406965A4 (en) 2025-12-17
TWI858393B (zh) 2024-10-11
KR20240082364A (ko) 2024-06-10
JP2024534545A (ja) 2024-09-20
AU2022350407B2 (en) 2025-09-04
JP2026097838A (ja) 2026-06-16
AU2022350407A1 (en) 2024-05-02
CN118119635A (zh) 2024-05-31
JP7864826B2 (ja) 2026-05-25
MX2024003535A (es) 2024-05-07
IL311643A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
MX2025000271A (es) Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
CL2025002681A1 (es) Anticuerpos anti-ceacam5 y sus conjugados y usos
AR115389A1 (es) Anticuerpo antagonista de cd73
CY1124799T1 (el) Παραγωγα πυριμιδινης ως ρυθμιστες υποδοχεα pge2
CO2021009302A2 (es) Receptores que ofrecen coestimulación específica para terapia adoptiva de células
PE20210110A1 (es) Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso
MX2024003535A (es) Proteina mutante de interleucina-2 y fusion de la misma.
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
CO2020015052A2 (es) Anticuerpos anti-cd63, conjugados y usos de estos
CO2021004789A2 (es) Piridazinonas y sus métodos de uso
EP4534107A3 (en) Protein complex by use of a specific site of an immunoglobulin fragment for linkage
MX2022005221A (es) Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso.
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
MX2021014961A (es) Compuestos triciclicos y su uso.
MX2023009874A (es) Anticuerpos anti-psma y estructuras car-t.
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
CO2023013550A2 (es) Polipéptido de unión a gucy2c y usos del mismo